# OnCo record paper-oreilly-hechtman-ntrk-fusion-pancreatic-larotrectinib-ann-oncol-2019 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-oreilly-hechtman-ntrk-fusion-pancreatic-larotrectinib-ann-oncol-2019/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-oreilly-hechtman-ntrk-fusion-pancreatic-larotrectinib-ann-oncol-2019" ;
  schema:name "Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion"@en ;
  schema:description "A woman whose pancreatic cancer carried a CTRC-NTRK1 fusion responded to larotrectinib for six months after chemotherapy failed, then developed resistance, showing both the promise and the limits of TRK inhibitors in this disease."@en ;
  schema:url <https://onco.cc/key-papers/paper-oreilly-hechtman-ntrk-fusion-pancreatic-larotrectinib-ann-oncol-2019/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1093/annonc/mdz385>, <https://pubmed.ncbi.nlm.nih.gov/31605106/> ;
  schema:sameAs <https://doi.org/10.1093/annonc/mdz385> ;
  schema:datePublished "2019"^^xsd:gYear ;
  schema:author "O'Reilly EM, Hechtman JF." ;
  onco:related <https://onco.cc/biomarkers/ntrk-fusion/> ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/kras-wild-type-pdac/> ;
  onco:targets <https://onco.cc/targets/ntrk/> ;
  onco:drugs <https://onco.cc/drugs/larotrectinib/> ;
  onco:institutions <https://onco.cc/institutions/mskcc/> ;
  onco:terms <https://onco.cc/terms/tumour-agnostic/> ;
  onco:people <https://onco.cc/people/eileen-oreilly/> ;
  onco:journals <https://onco.cc/journals/annals-of-oncology/> .